Latest news with #MarcKikuchi
Business Standard
16 hours ago
- Business
- Business Standard
Glenmark Pharma's US arm to launch Micafungin injection in the US market
Glenmark Pharmaceuticals announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, will launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), in the U.S. market this September. The product is bioequivalent and therapeutically equivalent to the reference listed drug Mycamine for Injection, 50 mg/vial and 100 mg/vial, originally developed by Astellas Pharma US, Inc. The company will begin distribution in September 2025. According to IQVIA sales data for the 12-month period ending June 2025, the U.S. market for Mycamine for Injection generated annual sales of approximately $60.7 million. Micafungin is an echinocandin antifungal used primarily in the treatment of candidemia, esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Marc Kikuchi, president & business head, North America said, We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need. Glenmarks Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is only approved for the indication listed in Glenmarks approved label. All brand names and trademarks are the property of their respective owners. Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmarks product is only approved for the indications listed in Glenmarks approved label and is not marketed for all RLD indications. IQVIA National Sales Perspectives: Retail & Non-Retail, June 2025. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company's consolidated net profit jumped 49.9% to Rs 215.48 crore on 7.4% rise in revenue from operations to Rs 1505.62 crore in Q1 FY26 over Q1 FY25. The scrip declined 1.38% to Rs 1,947.10 on the BSE.
News18
17 hours ago
- Health
- News18
Glenmark to launch injection to treat fungal infections in US
Agency: Last Updated: New Delhi, Aug 19 (PTI) Glenmark Pharmaceuticals Inc., USA on Tuesday said it will launch Micafungin for injection, used to treat fungal infections, in the US market. Micafungin for injection will be launched in strengths of 50 mg/vial and 100 mg/vial in a single dose, the company said in a statement. The company will begin distribution in September 2025, it added. The launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (single-dose vial) will grow the company's portfolio of products within the institutional channel, while also strengthening its commitment to bring quality and affordable alternatives to market for patients in need, Glenmark President & Business Head, North America Marc Kikuchi said. Glenmark's Micafungin for Injection 50 mg/vial and 100 mg/vial in single dose is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine for injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. Citing IQVIA sales data for the 12-month period ended June 2025, the company said the Mycamine ® for Injection, 50 mg/vial and 100 mg/vial, market achieved annual sales of approximately USD 60.7 million. PTI RKL SHW view comments First Published: August 19, 2025, 13:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy. Loading comments...
Business Upturn
20 hours ago
- Business
- Business Upturn
Glenmark Pharma to launch Micafungin for Injection USP in the US market
By Aman Shukla Published on August 19, 2025, 09:52 IST Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has announced the upcoming launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). The product is bioequivalent and therapeutically equivalent to the reference listed drug Mycamine® for Injection by Astellas Pharma US, Inc. (NDA – 021506). The company confirmed that distribution will begin in September 2025. According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine® for Injection market (50 mg/vial and 100 mg/vial) generated approximately $60.7 million in annual sales. Glenmark aims to capture a share of this market by offering a high-quality and more affordable alternative. Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, 'We are excited to introduce Micafungin for Injection USP, further strengthening our institutional product portfolio and reinforcing our commitment to deliver accessible, affordable, and quality medicines to patients in need.' The new launch is expected to expand Glenmark's presence in the U.S. injectable market while enhancing treatment options for patients. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
16-06-2025
- Business
- Yahoo
Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
MAHWAH, N.J., June 16, 2025 /PRNewswire/ -- Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC); compared to the active ingredient in Pataday®2 Once Daily Relief. According to Nielsen® syndicated data for the latest 52-week period ending May 17, 2025, the Pataday® Once Daily Relief (OTC) market3 achieved annual sales of approximately $50.0 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.2%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers." For product information and how to purchase, please visit: About Glenmark Pharmaceuticals Ltd. Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (Glenmark_pharma). References 1 Glenmark's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) is only marketed for the indications listed in Glenmark's approved drug facts label. 2 This product is not manufactured or distributed by Alcon Laboratories, Inc., distributor of Pataday® Once Daily Relief, and/or Novartis AG, owner of the registered trademark Pataday®, respectively. [Neither Alcon nor Novartis make or license Glenmark's product.] 3 Market includes brand and all available therapeutic equivalents. Note: Nielsen syndicated data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications. *Nielsen® NIQ Discover; Syndicated Data for Period Ending May 17, 2025 Logo: View original content: SOURCE Glenmark Pharmaceuticals Ltd Sign in to access your portfolio
Yahoo
20-03-2025
- Business
- Yahoo
Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
MAHWAH, N.J., March 20, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), determined by the FDA to be bioequivalent1 to Pataday®2 Once Daily Relief Ophthalmic Solution, 0.2% (OTC), of Alcon Laboratories, Inc. Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA. According to Nielsen® syndicated data for the latest 52 weeks' period ending February 22, 2025, the Pataday® Once Daily Relief Ophthalmic Solution, 0.2% (OTC) market3 achieved annual sales of approximately $50.7 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are pleased to continue to expand our OTC ophthalmic portfolio. The addition of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% highlights our commitment to meeting market needs and providing quality over-the-counter solutions for our customers." About Glenmark Pharmaceuticals Ltd. Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of cardio-metabolic, respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma). References: 1Glenmark's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) is only marketed for the indications listed in Glenmark's approved drug facts label. 2 This product is not manufactured or distributed by Alcon Laboratories, Inc., distributor of Pataday® Once Daily Relief, and/or Novartis AG, owner of the registered trademark Pataday®, respectively. [Neither Alcon nor Novartis make or license Glenmark's product.] 3Market includes brand and all available therapeutic equivalents. Note: Nielsen syndicated data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications. *Nielsen® NIQ Discover; Syndicated Data for Period Ending February 22, 2025 Logo - View original content: SOURCE Glenmark Pharmaceuticals Ltd
